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Supplemental arginine has shown promise as a safe therapeutic option to improve endogenous
nitric oxide (NO) regulation in cardiovascular diseases associated with endothelial dysfunction. Larginine, an endogenous amino acid, was reported in clinical studies in adults to improve
cardiovascular function in hypertension, pulmonary hypertension, pre-eclampsia, angina, and
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome.
L-citrulline, a natural precursor of L-arginine, is more bioavailable than L-arginine because of
hepatic first-pass metabolism avoidance and longer circulation time. Although not yet well
studied, arginine/citrulline has immense therapeutic potential in some life-threatening diseases of
children. However, optimal clinical development of arginine or citrulline in children is dependent
on more information about pharmacokinetics and exposure-response relationships at appropriate
ages and under relevant disease states. This article summarizes the pre-clinical and clinical studies
of arginine/citrulline in both adults and children, including currently available pharmacokinetic
information. The pharmacology of arginine/citrulline is confounded by several patient-specific
factors such as baseline variation of arginine/citrulline due to developmental ages and disease
states. Currently available pharmacokinetic studies are not enough to inform the optimal design of
clinical studies, especially those in children. Successful bench to bedside clinical translation of
arginine supplementation awaits information from well-designed pharmacokineticpharmacodynamic studies, along with pharmacometric approaches.
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L-arginine, a semi-essential amino acid that plays critical physiological roles in muscle
development and ammonia detoxification [1, 2], has been investigated for therapeutic use in
a wide variety of pathological conditions [3-5], in addition to its widespread use as an
ergogenic nutrition supplement [5]. Therapeutic arginine supplementation, as it improves
endogenous nitric oxide (NO) production, was mostly investigated for clinical use in the
ailments of the cardiovascular system that include hypertension, pulmonary hypertension,
angina, nitrate tolerance, and pre-eclampsia. L-arginine supplementation was reported to
restore normal endothelial function in both normotensive and hypertensive patients with
microvascular angina [6, 7]. Tolerance to the organic nitrates, a widely used NO donor for
the treatment of coronary artery diseases and chronic heart failure, remains as a longstanding therapeutic problem for which the nitrate-free treatment intervals remains as the
only option to prevent nitrate tolerance in the current clinical practice [8, 9]. Arginine
supplementation, as it restores the normal function of NO, has been useful in preventing
rapid nitrate tolerance from transdermal nitroglycerine use in patients with stable angina
[10]. Altered NO production is also contributing to the pathophysiology of pre-eclampsia
and intrauterine growth restriction [11]. Supplemental arginine during pregnancy was found
to reduce the incidence of pre-eclampsia in the high-risk pregnant population [12].

Author Manuscript

Arginine is also a promising therapy for pulmonary hypertension (PH), a devastating cardiopulmonary disease with a high mortality rate [13]. Clinical studies in adults showed that
arginine supplementation, administered either in the form of arginine or its pre-cursor,
citrulline, improves pulmonary hemodynamics in PH-afflicted adults [14-16]. Although
aspects of the underlying pathophysiology for PH may differ from the adult disease, use of
arginine/citrulline supplementation for PH in children (idiopathic or disease-associated) is
also receiving attention [17-21] .
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There is also evidence that arginine may be therapeutically useful in some life-threatening
inherited diseases in children that are accompanied by cardiovascular complications.
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
syndrome, a progressively fatal mitochondrial disease, is caused by genetic mutations in the
mitochondrial DNA. In MELAS syndrome, endothelial dysfunction, because of uncontrolled
mitochondrial proliferation, leads to alterations in cerebral hemodynamics and stroke-like
episodes. Published literature shows that supplemental arginine can replenish NO deficiency
and thus can improve blood circulation in the cerebral microvasculature [22, 23]. A recently
published clinical study suggests that arginine supplementation, either in the form of
arginine or citrulline, appears to have therapeutic benefits in children with MELAS
syndrome [24].
Urea cycle disorders (UCD) are another group of diseases that affect young children. In
UCD, inherited deficiencies of some key enzymes and transporters of the urea cycle pathway
Paediatr Drugs. Author manuscript; available in PMC 2021 June 01.
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results in the accumulation of ammonia and some precursor metabolites causing severe
neurological damages [18, 25]. For the last two decades, supplemental arginine was useful in
improving clinical outcomes in children with UCD [26, 27]. Arginine therapy replenishes
the deficient urea cycle intermediates by activating alternative enzymatic pathways [27, 28].
In clinical studies, supplemental arginine therapy has been used either as direct L-arginine or
in the form of arginine precursor—citrulline. Citrulline, an alpha-amino acid that is
metabolized to L-arginine, when given orally, is more effective than L-arginine in improving
arginine plasma concentration because it is not the substrate of hepatic or intestinal arginases
[5].

Author Manuscript

Although arginine supplementation possesses tremendous therapeutic potential in some lifethreatening diseases of children, the clinical pharmacology of arginine/citrulline therapy—
particularly pharmacokinetics, exposure-response relationship, and safety— has not been
investigated extensively in the pediatric population. In this review, we summarize the
molecular basis of arginine/citrulline supplementation in different diseases,
pharmacokinetics, and pharmacodynamics of arginine/citrulline in their potential therapeutic
uses in adult and pediatric diseases. We discuss the relationship between pharmacokinetic
exposure and therapeutic response of arginine/citrulline in pre-clinical studies with its
possible translation towards clinical studies. This article will serve as a ready reference as
there is a lack of review of arginine/citrulline supplementation regarding its
pharmacokinetics and potential therapeutic uses in pediatric diseases.

L-arginine deficiency in vascular endothelial cell dysfunction and the use of
citrulline as an efficient arginine supplement
Author Manuscript
Author Manuscript

Regulation of vascular tone and contractility is critically dependent on the availability of Larginine, a significant substrate for NO production in the vascular endothelium. Inadequate
supply of L-arginine resulted in increased superoxide generation by eNOS and altered Larginine metabolism within the vascular endothelial cells. Prolonged deficiency of Larginine further causes elevated oxidative stress, sequestration of intracellular L-arginine,
and slower recycling of L-arginine from its precursor–L-citrulline. As a result,
vasoconstriction and vascular remodeling occur as hyperactive eNOS fails to produce
enough NO [29-31]. Published studies have shown that supplemental arginine can prevent
endothelial dysfunction and thus can restore the normal vasodilatory capacity of the vascular
endothelium. However, due to the presence of arginase in intestinal enterocytes and the high
first-pass metabolism of L-arginine to ornithine and urea by the liver arginases, oral arginine
supplementation cannot sufficiently elevate the plasma levels of L-arginine [32, 33].
Moreover, higher levels of circulating L-arginine induce arginases in most of the tissues
resulting in rapid L-arginine clearance.
L-citrulline, a natural precursor of L-arginine that takes part in both urea and NO cycles, can
be a better substitute of L-arginine supplementation because it bypasses hepatic first-pass
metabolism and can be converted to L-arginine specifically within the tissues (Fig.1). Lcitrulline is an intermediate product of urea cycle in which L-ornithine, a metabolite of Lglutamine, is converted to L-citrulline by ornithine carbamoyltransferase. With development,
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L-citrulline becomes a useful product of small intestine in human as compared to L-arginine
and, the kidney, the primary organ of L-citrulline metabolism, gradually becomes more
efficient in converting L-citrulline to L-arginine in the post-natal period. In other words, Lcitrulline, when taken orally, can effectively improve L-arginine plasma levels as it is
transported into enterocytes without metabolic loss by arginase and because it then bypasses
hepatic metabolism and is transported to the kidneys where it is metabolized to L-arginine
[33]. These elements of L-citrulline processing provide pharmacokinetic advantages over Larginine. Consequently, orally administered L-citrulline is expected to result in
comparatively higher concentrations of L-arginine and hence, can bring about more
significant therapeutic benefits than orally administered L-arginine. Thus, L-citrulline
supplementation is considered as a better alternative to L-arginine supplementation in a wide
variety of diseases caused by L-arginine deficiency.
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Preclinical studies exploring the use of L-arginine supplementation in
various diseases
Pre-clinical studies are necessary when investigating novel drugs/supplements to establish
safety and proof of concept for efficacy before initiating clinical trials in humans, especially
in vulnerable populations such as pediatric or pregnant populations. The use of in vivo
(whole animal) or ex vivo (isolated organ) models for assessing safety and efficacy provide a
basis for understanding the potential effects size in humans as well as the possible side effect
profile.
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The use of citrulline and L-arginine has been investigated pre-clinically in some diseases and
different animal models. This section focuses on atherosclerosis (vascular wall and vascular
function), systemic hypertension, pulmonary hypertension, and preeclampsia. Table 1
summarizes the pre-clinical studies conducted in these diseases as well as the outcome of
arginine or citrulline supplementation.

Author Manuscript

As described in the previous section, NO is vital to maintain vascular endothelial function.
As such, the significant effect of arginine/citrulline supplementation is to improve
endothelial function in both [34-39] systemic and pulmonary vasculature [40-44] Notably,
the improvement in endothelial function results in downstream benefits such as decreased
vascular/pulmonary pressure or normalization of vascular wall intimal thickness [34-36, 45].
As an example, the vascular wall effects of L-arginine supplementation are summarized in
the review by Preli et al. [46]. The dominant animal model used in this setting is the
hypercholesteremic rabbit (high cholesterol chow). Briefly, L-arginine supplementation
reduces the surface area of atherosclerotic lesions and reduces the intima thickness
compared to untreated animals (Table 1) Furthermore, another study used LDL receptor
knockout mice and showed that L-arginine prevented the formation of xanthomas. The
authors of this paper concluded that L-arginine supplementation might be of benefit to the
patients with familial hypercholesterolemia. L-arginine supplementation also reduced
systemic blood pressure in both salt-sensitive hypertension [47] and spontaneous
hypertension rat models[48] , as well as in different animal models for preeclampsia,
including insulin-induced hypertension [49, 50] and adriamycin-induced nephropathy
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models [51, 52]. The link between arginine/citrulline supplementation improved NO
production, and vascular function has been shown in ofseveral animal models investigating
pulmonary hypertension. Intact animal as well as ex vivo models for pulmonary
hypertension were developed either with environmental injury (hypoxia) [40-42, 53], or
drug-toxin-induced (monocrotaline) injury [44]. L-arginine supplementation, when tested in
these models, increased NO production [41, 40, 47, 48, 53, 42, 44] that ultimately resulted in
a reduction of pulmonary vascular resistance [40-44] (Table 1). Similarly, L-citrulline
supplementation was effective in improving pulmonary vascular NO production and
ameliorating pulmonary hypertension when investigated in newborn/juvenile animal models,
for example, newborn pigs [40, 41, 53] and young rats [48].
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The effect of arginine supplementation was also evaluated in some preclinical models
representing systemic hypertension. L-arginine or L-citrulline intake improved NO synthesis
and prevented salt-sensitive hypertension in rats [47]. A recently published study showed
that L-citrulline supplementation prevents spontaneous hypertension in rats [48].
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These preclinical studies, although demonstrating the efficacy of arginine/citrulline
supplementation in a wide variety of pathologic conditions, suffer limitations. One limitation
is the dearth of studies using age or physiologically appropriate (i.e., pediatric/juvenile or
pregnant animal models. Also, many of the studies involved short-term exposures and have
not sufficiently addressed safety concerns. One animal study investigated the toxicity of Larginine over 13 weeks in rats; overall, the side effects were minimal and generally transient
[54]. Theoretically, an overdose of arginine/citrulline may result in hypotension due to its
vasodilatory effects. Published articles show that large doses of L-arginine are used in
preclinical models to induce acute pancreatitis [55], and an accidental overdose of arginine
hydrochloride was fatal [56]. No adverse side effects have been reported in studies with
citrulline, although only a limited range of doses have been used. Thus, the safety of
arginine supplementation remains of concern, and mandates that safety issues be carefully
considered, and adverse effects closely monitored for when a clinical translation is done.

Clinical use of arginine supplementation

Author Manuscript

Therapeutic effects of L-citrulline are mostly dependent on the action of L-arginine. Larginine is generated from L-citrulline by argininosuccinate synthase as part of the urea
cycle (Figure 1). As a substrate for nitric oxide synthases (NOS), L-arginine is integral to the
formation of NO, and reformation of the precursor L-citrulline. NO is a cofactor for soluble
guanylate cyclase, catalyzing the formation of cyclic guanosine monophosphate (cGMP), a
regulator, mediator, and messenger in the nervous, immunologic, and cardiovascular
systems. In the vasculature, cGMP is a regulator for vasodilation. As dysfunctional NO
signaling causes a wide variety of diseases, supplemental arginine in the form of L-arginine
or L-citrulline was evaluated in different clinical studies as summarized in Table 2.
Supplemental arginine/citrulline in adult clinical studies
Clinical studies in adults have evaluated the effect of dietary supplementation with citrulline
or citrulline-rich watermelon, in improving exercise outcomes [57, 58] and cardiovascular
health, including pulmonary hypertension [59-77]. Although clinical studies in the
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mid-1990s were not in agreement on the benefits of arginine supplementation in pulmonary
hypertension [78-81], recent studies have more consistently supported the beneficial effects
of arginine/citrulline in adults with cardiovascular problems [76, 82]. Oral L-citrulline
administration for two weeks was associated with improvement in the quality of life of
patients with idiopathic pulmonary hypertension [15]. Three studies assessed the effect of
arginine supplementation in angina pectoris related complications. Egashira et al. showed
that intracoronary infusion of L-arginine improved coronary microcirculation in patients
with angina pectoris but not in control subjects who had atypical chest pain and normal
coronary angiogram [6]. L-arginine supplementation in this study was associated with the
improvement in endothelium-dependent vasodilation. Eight years later, in another clinical
study, Palloshi et al. found oral L-arginine supplementation to be a useful way to improve
endothelial function in hypertensive patients with angina [7]. Supplemental arginine, in a
separate study, effectively prevented nitrate tolerance, a significant limitation of organic
nitrates that are used as first-line therapies for managing angina pectoris. In this randomized,
placebo-controlled double-blind study, oral L-arginine therapy showed beneficial effects in
preventing nitrate tolerance during continuous transdermal nitroglycerin study [10].
Arginine/citrulline supplementation was effective in managing symptoms associated with
MELAS syndrome [83] and in cystic fibrosis-associated airway obstruction[84]. However,
arginine supplementation was not effective in improving acute myocardial infarction or
tuberculosis outcome [85, 86].
Supplemental arginine/citrulline in pediatric clinical studies
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Brusilow et al. first showed that arginine supplementation could ameliorate symptomatic
hyperammonemia in a pediatric patient with inborn errors in urea synthesis [26]. In 2001,
Waugh et al. reported a pilot phase-II clinical trial with five pediatric participants (ages 10–
18 years) with sickle cell disease. This study found that administration of 0.09 to 0.13 g/kg
of oral L-citrulline twice daily for four weeks increased plasma arginine concentrations by
65%, and normalized leukocyte and neutrophil counts. Based on these results and positive
perceptions by the patients, the authors suggested L-citrulline be used as palliative therapy
although pharmacokinetic exposure of L-citrulline was not studied in this study. This pilot
study, although showed encouraging results, suffered through significant limitations such as
small sample size, the absence of controls, was not definitive on a dose, and measured
outcomes within the designated 4-week period. In recognition of these limitations, the
authors recommended additional well-controlled, long-term studies to be conducted [87].
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In 2006, Smith et al. reported a randomized, placebo-controlled trial of 40 children
undergoing surgery with cardiopulmonary bypass given oral L-citrulline supplementation in
preventing postoperative pulmonary hypertension. Administration of a total of 9.5 g/m2 Lcitrulline perioperatively was associated with ~85% increases in mean arginine and Lcitrulline plasma concentrations 12 hours after surgery. This is the largest of the reported
pediatric studies. Study observations included citrulline concentrations below the agespecific norms for participants that developed postoperative pulmonary hypertension [88].
Determination of optimized L-citrulline dosing was outside the study scope, and the study
revealed that controls for baseline citrulline concentrations are of potential consequence in
future studies.
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In 2016, El-Hattab et al. reported a controlled crossover study of 5 pediatric patients with
MELAS syndrome, with five healthy pediatric participants serving as controls, given
citrulline and arginine. Participants with a bodyweight of at least 20 kg were given 10
g/m2/day of the supplement. Supplementation was 3 g/kg/day in participants with weights
below 20 kg. In comparison to arginine supplementation, supplementation with L-citrulline
resulted in higher increases in nitric oxide production rate, arginine and citrulline flux,
plasma arginine and citrulline concentrations, and de novo arginine synthesis rates [24].
One additional study in 2017 by Stepanova et al. showed that treatment with citrulline
maleate improved serum concentrations of L-arginine, nitrite, and NO metabolites in
pediatric patients who presented signs of endothelial dysfunction [89].

Author Manuscript

Overall, recent clinical studies in both adult and pediatric populations provide evidence for
supplemental arginine/citrulline associated improvement in efficacy outcomes, although the
exposure-response correlation and dose-ranging effects are yet to be well evaluated. These
studies create the ground of confidence for future well-designed, randomized clinical trials
that will establish efficacy and will inform dosing decisions for arginine supplementation in
both pediatric and adult diseases. However, the optimal design of future clinical trials
depends on accurate information about the pharmacokinetics of arginine/citrulline.

Evaluation of arginine and citrulline pharmacokinetics in pre-clinical
studies

Author Manuscript

The pharmacokinetics of supplemental arginine is complex because this endogenous
molecule shows variable basal levels and contributes to multiple biochemical pathways.
Arginine exposure and clearance after supplementation are influenced by the patients’ age
and the types and stages of the targeted diseases. Wu et al. evaluated the pharmacokinetics of
arginine in different animal models [90]. Regardless of the physiologic, pathologic and
species differences in these animals, intravenous supplementation of arginine increased
plasma arginine levels, but it returned to the baseline with 4-5 hours after administration.
Higher clearance of arginine in intravenously administered animals was observed in
pregnant, neonatal, and lean animals when compared to that of their counterparts–nonpregnant, adult and obese animals, respectively. Oral supplementation results in variable
absorption kinetics of arginine due to the interplay of intestinal absorption and gut
metabolism. However, clearance of arginine followed a similar trend as observed in the case
of intravenous dosing. Circulating arginine undergoes rapid clearance in animals of different
stages of physiological maturation.
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Disease states can influence the basal levels of arginine and citrulline. Effect of arginine
supplementation, either by arginine or citrulline, on its PK, was evaluated in different animal
disease models. Alloxan-induced diabetic rats showed reduced basal levels of arginine that
can be restored to the normal levels with arginine supplementation [91]. To evaluate the
effects of NO in different CNS disorders, Heinzen et al. reported a pharmacokinetic (PK)pharmacodynamic (PD) model of exogenous arginine supplements that can successfully
predict arginine levels in the brain [92]. PK-PD model obtained from this study suggests that
exogenous arginine supplementation increased hippocampal arginine concentration in a

Paediatr Drugs. Author manuscript; available in PMC 2021 June 01.

Rashid et al.

Page 8

Author Manuscript

dose-dependent fashion. Another study evaluated the effect of oral arginine plus citrulline
therapy in augmenting NO-dependent responses in animal models of cardiovascular diseases
[93]. Oral combination of arginine and citrulline showed a shorter Tmax, the time to reach
maximum arginine concentration in plasma, than that of the single L-citrulline therapy in
human suggesting an advantage of short-acting effects if interspecies differences in
absorption between rat and human are negligible. While citrulline-only supplements support
the long-acting enhancement of arginine availability, the benefits of citrulline plus arginine
therapy as a rapid-acting arginine supplement requires validation through human studies.
Choice of supplements can also be dependent on the pathologic conditions. Infectious
conditions such as endotoxemic sepsis can severely reduce citrulline bioavailability,
although arginine pharmacokinetics remains largely unaltered [94].
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Although preclinical research is generating impressive evidence supporting the therapeutic
efficacy of supplemental arginine/citrulline in a wide variety of pathological conditions,
studies reporting arginine pharmacokinetics are minimal in number, sporadic regarding
study objectives, and challenging to translate to human. Significant challenges in studying
arginine exposure after supplementation include the estimation of highly variable baseline
and the prediction of disease-associated alterations in arginine biosynthesis. Ultimately, for
accurate translation to clinical trials, PK information must be generated in humans.

Pharmacokinetics of arginine and citrulline in human
To date, most of the clinical studies that explored the pharmacokinetics of supplemental
arginine were conducted in a healthy adult population. Clinical studies that evaluated the
pharmacokinetics of arginine or citrulline are summarized in Table 3.

Author Manuscript

Arginine/citrulline supplementation in a healthy adult population
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Tangphao et al. tested exogenous arginine in healthy humans as an initial effort to
understand the pharmacokinetics of L-arginine in patients with cardiovascular diseases [95].
Basal L-arginine levels in untreated healthy adults showed a substantial diurnal variation.
Baseline corrected plasma L-arginine concentrations measured after oral or intravenous Larginine administrations showed a bi-phasic elimination pattern [95]. Intravenous L-arginine
administration triggered an initial concentration-dependent rapid renal elimination followed
by a slower elimination mainly guided by non-renal elimination. A 10g single dose of oral
L-arginine having a ~20% bioavailability caused a three-fold increase in plasma L-arginine
concentration from the baseline [95]. Schwedhelm et al. reported that chronic oral
administration of citrulline dose-dependently increased the concentration of L-arginine in
healthy adults [96]. In this randomized, double-blind, placebo-controlled study, different
doses of L-citrulline were compared with two different formulations of L-arginine. Lcitrulline, with a one-half the dosage strength of L-arginine, was associated with similar
plasma exposure of L-arginine suggesting an efficient way of L-arginine supplementation.
Like previous studies, determination of plasma L-arginine half-life was not possible due to
irregular baseline values. They reported Tmax and Cmax for both citrulline and arginine
after a 3 g dose of citrulline: Tmax = 0.7±0.1 h and 1.4±0.1 h, and Cmax = 846±45μmol/l
and 149±42 μmol/l, respectively [96]. Another study that characterized the pharmacokinetics
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of citrulline in healthy adults for four oral doses (2, 5, 10, and 15 g). A dose-dependent
significant decrease in clearance was observed for 2, 5, and 10 gm doses, although mean
distribution volumes for each dose was similar [97]. L-citrulline doses of 10 gm or greater
were associated with ~50% decrease in clearance than that of the 2-gm dose. Plasma halflife and exposure of citrulline also increased dose-dependently and the Tmax and Cmax
were determined for both citrulline (Tmax = 0.72±0.08 h, Cmax = 2756±70 μmol/l) and
arginine (Tmax = 1.67±0.05 h, Cmax = 280±1043 μmol/l) [97]. In 2007, Rouge et al.
reported results from a randomized study of 10 healthy volunteers. Supplementation with
0.18 g/kg/day citrulline resulted in increases of citrulline and arginine plasma
concentrations. Plasma concentrations of citrulline increased from 39±4 to 225±44 μmol/L,
and arginine increased from 134±33 to 247±62 μmol/L. This supplementation enhanced
nitrogen balance, increased levels of RBC-bound citrulline as well as the renal clearance of
citrulline [98]. Few studies evaluated whether citrulline-rich dietary intervention can
improve plasma citrulline/arginine levels. Mandel et al. observed significant increases in
both arginine and citrulline within the first two hours after ingestion of 3.3 kg (wet weight)
of watermelon by six healthy adults. Citrulline increased from 22 μmol/L to 593 μmol/L
(range 386 - 1069) 1 hour after ingestion and Arginine increased from 65 μmol/L to 199
μmol/L (range 128 - 251) 2 h after ingestion [99]. In 2007, Collins et al. also reported
increases in plasma arginine in 23 healthy adults given watermelon juice: 780 g or 1560 g
for three weeks, resulting in 12% and 22% increases in plasma arginine concentrations,
respectively [100].
Arginine/citrulline supplementation in adult patients with disease states
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As a step forward to their previous study in healthy adults, Tangphao et al. evaluated
pharmacokinetics of L-arginine in hypercholesterolemic patients who are reported to have
impaired nitric oxide signaling in the endothelium and platelets [101]. Long-term (~12
weeks) administration of oral or intravenous L-arginine was associated with a significant
increase in plasma L-arginine level in patients with hypercholesterolemia. A previous study
in rabbit suggested that long-term treatment with exogenous arginine caused a gradual
decline in plasma L-arginine levels [102]. However, this study showed a sustained increased
level of plasma L-arginine after oral or intravenous administration. Although authors were
not able to calculate two key parameters—distribution volume and elimination half-life of Larginine due to diurnal variation of basal L-arginine levels. Exogenous L-arginine treatment
did not show pharmacodynamic tolerance to plasma L-arginine induced growth hormone
release [101].
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L-arginine pharmacokinetics was also evaluated in severe malaria-affected patients who
showed lower than normal plasma L-arginine levels due to malaria-associated endothelial
dysfunction [103]. In a prospective observational study in healthy and malaria-afflicted
subjects, dose-ranging effect of intravenous L-arginine infusion in replenishing plasma Larginine level was determined by using a population pharmacokinetic approach. Plasma
concentration-time profiles of a 30-minute infusion, for all the doses of 3, 6, or 12 g,
supported a two-compartment linear model with first-order elimination. With an estimated
clearance of 733 mL/min, exogenous L-arginine showed a slightly shorter half-life in
malaria afflicted patients than that in healthy subjects. Simulations of plasma profiles for 12
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g dose of L-arginine at different dosing frequencies-- 6, 8, and 12 hr.-- predicted a 60%,
75%, and 90% increase, respectively, above the required half-maximal saturating
concentration at L-arginine transporter for optimal NO production [103]. In a separate openlabel pilot study, a 12g dose of L-arginine given every 8-hourly was associated with lower
than the previous model predicted concentrations and a 40% increased L-arginine clearance
in patients with severe malaria than that in moderately-severe malaria patients [104, 103].
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In 2012, El-Hattab et al. reported a controlled crossover study of 20 participants: 10 patients
with MELAS syndrome and ten healthy participants given 10 g/m2/day oral citrulline or
oral arginine. Supplementation with citrulline resulted in more significant increases in nitric
oxide production rate, arginine and citrulline flux, and plasma arginine and citrulline
concentrations. Citrulline supplementation increased plasma arginine concentration from
57.6±2.1 to 182.0±14.4 μmol/L; arginine supplementation increased plasma arginine
concentration from 57.1±3.2 to 143.8±9.9 μmol/L. De novo arginine synthesis was observed
to decrease with arginine supplementation and increase with citrulline supplementation
[23] .
The pharmacokinetic and safety profile of intravenously administered L-citrulline has
recently been evaluated in adults, ages 18-24, with sickle cell disease [105]. In this dosefinding study, a bolus dose of 20 mg/kg followed by a 7 mg/kg/h continuous infusion of
citrulline was able to maintain a trough plasma arginine concentration of 100 μmol/l. IV
bolus administration of citrulline resulted in a mean maximum plasma citrulline
concentration of 259 μmol/l [105]. .
Arginine/citrulline supplementation in pediatric patients
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The PK of intravenously administered L-citrulline was evaluated in children undergoing
congenital cardiac surgery [19]. In the first group of patients, intravenous bolus doses
ranging between 50 mg/kg and 150 mg/kg were implemented to achieve a 4-hr trough
citrulline plasma concentration of 80-100 μmol/L. Pharmacokinetic simulations based on
this data suggested a bolus dose of 150 mg/kg followed by an intravenous infusion (9 mg/
kg.hr) after 4 hours to maintain optimum citrulline levels. The half-life of citrulline was
reported to be approximately 60 minutes with a distribution volume ranging between 0.8 and
1.0 L/kg [19]. However, the effect of citrulline administration in increasing the plasma level
of the active compound L-arginine was not measured. In pediatric patients with MELAS,
citrulline supplementation showed a 4-fold increase in plasma arginine concentration
(64±5.7 to 257±21 μmol/L) from baseline. Arginine supplementation also showed a modest
increase in plasma arginine concentration (59±5 to 184±14 μmol/L)[24].

Author Manuscript

All the clinical studies that report the pharmacokinetics of arginine/citrulline after
exogenous arginine supplementation in the form of arginine or citrulline or citrulline-rich
diet showed an increase in plasma arginine because of the intervention. Clearance of
arginine/citrulline is dependent on the dose of citrulline/arginine, age, and the disease state
although high variation in baseline arginine/citrulline precludes the accurate estimation of
distribution volumes and clearances. These variables must be considered when designing
clinical trials that evaluate the efficacy of arginine/citrulline in different age groups suffering
from various disease states.
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Pharmacometric approaches to evaluate arginine pharmacokinetics
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There has been minimal work published for assessing the population pharmacokinetics of
arginine and citrulline [103]. Yeo et al. investigated the L-arginine pharmacokinetics in adult
patients with moderately severe malaria and developed a two-compartment model to
describe the concentration-time profiles. Bodyweight and ethnicity were found to influence
the PK in patients with malaria disease, although these covariates were not identified in
previous analysis with healthy volunteers. Additionally, an empirical second-order
polynomial equation was used to describe the increase in endogenous L-arginine levels over
time in patients who did not receive exogenous arginine. For baseline arginine description,
an alternative turnover model parameterizing the endogenous production of arginine was
also evaluated but not retained, due to the model sensitivity to initial estimates. In another
study with healthy Chinese volunteers, Wang et al. applied a similar two-compartment
model structure to describe the L-arginine PK [106]. The final parameter estimates were
comparable between the two modeling attempts. However, in the latter study, weight was
identified as a significant covariate on peripheral volume, and the baseline was not
specifically described in the model. By the time of this review, there were no published
studies on citrulline population PK.

Author Manuscript

The limited number of publications on arginine and citrulline population modeling and
inconsistency in published models has indicated the gap of knowledge in understanding the
exposure-response relationship of these drugs in patients. More studies are needed to
establish PK and PD characteristics of arginine and citrulline, their population variability,
and potentially influential factors from patient features. Especially considering the
endogenous functionality of these molecules, study design should accommodate appropriate
sampling strategies to describe the natural progression of baseline arginine/citrulline levels
in patients. Metabolism of arginine and production of nitric oxide has been shown to
influence by disease status [107-109]. Therefore, when developing quantitative models for
these molecules, disease status should also be evaluated as potential covariates for both
exogenous and endogenous molecule kinetics.

Conclusion

Author Manuscript

Supplemental arginine, primarily because of its crucial role as an endogenous amino acid
substrate in nitric oxide regulation, has shown potential for therapeutic use in different
diseases in both adult and pediatric age groups and in both pre-clinical and clinical studies.
Currently, supplemental arginine is available as intravenous or oral dosage forms of arginine.
The arginine precursor, citrulline, is available in oral forms and an IV preparation is being
investigated in clinical trials of children undergoing cardiopulmonary bypass surgery but is
not yet available. Ingestion of watermelon, a citrulline rich fruit, has also been used in
clinical studies to improve arginine levels. Citrulline appears to be more efficient than
arginine in enhancing systemic arginine concentration. Although in several clinical studies,
arginine/citrulline supplementation effectively improved some life-threatening conditions in
the pediatric population, the widespread clinical application is limited because PK data and
the dose-response relationship of arginine/citrulline requires further evaluation. Arginine
follows complex pharmacology that depends on several confounding factors, e.g., baseline
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variation of arginine due to developmental and disease state, age, disease condition,
pregnancy, etc. Pharmacokinetic studies of arginine/citrulline in diseased or special
populations are inadequate to inform appropriate dosing guidance. Research directed
towards understanding the pharmacokinetic-pharmacodynamic relationship of arginine,
given either as arginine or citrulline supplements, in different age groups and disease
conditions is critically essential in its bench-to-bedside translation.
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Key points
Arginine/citrulline has immense therapeutic potential in some life-threatening diseases of
children including cardiovascular function in hypertension and pulmonary hypertension.
The pharmacology of arginine/citrulline is impacted by several patient-specific factors
such as baseline variation of arginine/citrulline due to developmental ages and disease
states.
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Figure 1:

Arginine and citrulline: two significant players in the urea and nitric oxide cycles
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Table 1

Author Manuscript

Summary of different pre-clinical studies with arginine/citrulline supplementation

Author Manuscript

Disease

Animal model

The outcome of L-arginine or citrulline
supplementation

Atherosclerosis

Hypercholesterolemic rabbit
LDL receptor knockout mouse

- ↓ lesion surface area[110, 34, 38, 35]
- ↓intima thickness[34-36, 45]
- Absence of adherent monocytes or tissue macrophages[45]
- Prevents xanthoma formation[110]

Vascular endothelial
function

Hypercholesterolemic rabbit

- ↑ Endothelial dependent relaxation [34-39]
- ↑NO production/superoxide radical release[34, 39, 38, 111]

Pulmonary
hypertension

Hypoxia-induced pulmonary hypertension (rat and
newborn pig)
Monocrotaline-induced pulmonary hypertension
[43]

- ↑NO production [40, 42, 44, 53]
- ↓Pulmonary vascular resistance[40-44]

Systemic hypertension

Salt-sensitive hypertensive (rats)
Spontaneous hypertension (young rat)

-↑NO production[48, 47]

Preeclampsia

Insulin induced hypertension (pregnant rat)

- ↓Blood pressure[49, 51, 50, 52]
- ↓urinary metabolites or nitrate[49, 51, 50, 52]
- ↓urine protein excretion[51, 52]

Adriamycin-induced nephropathy (pregnant rat)

↓=decrease; ↑= increase; LDL= Low Density Lipoprotein; NO= Nitric Oxide; PAH=Pulmonary Arterial Hypertension
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Table 2

Author Manuscript

Clinical studies on arginine/citrulline supplementation in different diseases
Disease

Study population

Clinical outcome

Author Manuscript
Author Manuscript

Age
(yrs.)

n

Dosing

Inborn errors of
ureagenesis [26]

<0.5

4

Arginine/citrulline 0.2
mmol/kg/day

- Arginine supplementation improved
symptomatic hyperammonemia

Angina pectoris [6]

Angina=57±9
Control=59±8

16; microvascular
angina=8, control=8

Arginine 500 mg as
10-minute infusion

- Arginine supplementation improved
endothelium-dependent vasodilation in the
coronary arteries

Angina pectoris [7]

Angina=57±9
Control=59±8

13

Arginine 2g, tid oral

- Arginine supplementation improved
endothelial function in hypertensive
patients with microvascular angina

Preeclampsia [12]

Placebo=28.2±5.1
Arginine=28.0±6.1

450; Placebo=222,
Arg=228

Arginine 6.6g/day
oral

- Arginine supplementation prolongs the
latency to development of pre-eclampsia

Nitrate tolerance in
patients with angina
[10]

14; arginine=7,
placebo=7

Arginine 700 mg oral

- Arginine supplementation modified or
prevented the development of nitrate
tolerance during continuous transdermal
nitroglycerine therapy

Sickle cell disease
[87]

10-18

5

Oral Cit 0.1 g/kg bid

- ↓Total leukocyte & segmental neutrophil
count
- Symptomatic improvement
- No controls used

Postoperative
pulmonary
hypertension [88]

<6

40; Placebo=20,
Cit=20

5 post-operative doses
of Cit 1g/m2

- Citrulline supplementation elevated
plasma arginine/citrulline concentration
- Elevated citrulline in plasma prevented
post-operative pulmonary hypertension

MELAS syndrome
[24]

6-14

10; Placebo=5, Cit/
Arg=5

3 g/kg/day; Cit/Arg

- Citrulline supplementation is more
effective than arginine in improving NO
production

MELAS syndrome
[23]

20-46

20; Placebo=10, Cit/
Arg=10

0.8 g/kg/day; Cit/Arg

- Citrulline supplementation substantially
increased NO production than that
observed with arginine supplementation

Acute myocardial
infarction [85]

>30

153; Placebo=75, Cit/
Arg=78

1-3gm tid for six
months

- No improvement in vascular stiffness or
ejection fraction
- Might be associated with higher
postinfarction mortality
- L-arginine supplementation should not
be recommended in acute MI

Tuberculosis [86]

15-73

200; Arg+vitD=50,
Arg+placebo=49,
placebo+vitD=51, all
placebo=50

Arg=6 g daily as oral
tablet; 1250 mcg
vitD3 as oral tablet

- L-arginine supplementation has no effect
on tuberculosis outcome

Pulmonary
hypertension [79]

52±5

Pulmonary
hypertension=10
Heart failure without
PH=5

30-minute infusion of
arginine (500 mg/kg)

- Exogenous L-arginine is beneficial in
some patients with pulmonary
hypertension in short-term

Cystic fibrosis
associated airway
obstruction [84]

14-45

13 patients with cystic
fibrosis

18 mL of 7% arginine
HCl solution given
through an electronic
nebulizer

- Single inhalation of arginine results in an
acute and transient improvement of
pulmonary function and oxygenation

Author Manuscript

‘>‘= greater than; ‘<‘= less than; Arg=arginine; Cit= citrulline; g= gram; kg= kilogram; m2= meter squared; mcg= microgram; mg=milligram;
mmol= millimole; PAH=Pulmonary Arterial Hypertension; tid= three-times daily; vit = vitamin
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Table 3

Author Manuscript

Clinical studies reporting the pharmacokinetics of arginine/citrulline

Author Manuscript
Author Manuscript
Author Manuscript

Study type

Subjects

Dosage

PK outcome

Randomized placebocontrolled study [14]

19 subjects with
precapillary pulmonary
hypertension

Oral 50 mg/kg L-arginine

- Plasma L-arginine: from 90±4 (baseline) to
274±34 (statistically significant change from
baseline)

Phase 1 dose escalation [19]

5 infants and children
undergoing cardiac
surgery for congenital
problems

Stepwise dose escalation: 50
mg/kg, 100 mg/kg and 150
mg/kg; two doses were
administered-- one before the
surgery and one immediate
after the surgery.

- Citrulline plasma clearance, distribution-volume
and half-life was 0.6 Lhr−1kg−1, 0.9 Lkg−1 and 1
hour, respectively

Controlled study on subjects
with MELAS syndrome [23]

20 subjects (10 with
MELAS syndrome and
10 healthy subjects)

L-arginine or L-citrulline: 10
g per m2 body surface area per
day for two days.

- Arginine supplementation: plasma arginine
increased from 57.1±3.2 (baseline) to. 143.8±9.9
(statistically significant change from baseline)
- Citrulline supplementation: plasma arginine
increased from 57.6±2.1 (baseline) to. 182±14.4
(statistically significant change from baseline)

Controlled crossover study
[24]

Five pediatric patients
with MELAS
syndrome and five
healthy children as
control

Citrulline/Arginine dose:
Patients weighing < 20 kg:
500 mg/kg/dose given orally
every 4 hours for 48 hours.
Patients weighing ≥ 20 kg: 10
g/m2/day.

- Citrulline supplementation increased plasma
arginine concentration from 64±5.7 to 257±21
μmol/L;
- Arginine supplementation increased plasma
arginine concentration from 59±5 to 184±14
μmol/L

Pilot study in patients with
pulmonary hypertension [79]

10 subjects with
pulmonary
hypertension

500 mg/kg of L-arginine as
30-minute infusion

Plasma arginine increased from 59±6 μmol/L to
10,726±868 μmol/L (statistically significant
change)

Pilot phase-II clinical trial
[87]

Five sickle cell disease
patients (ages 10-18)

0.09 to 0.13 g/kg twice daily
for four weeks

- Increase of 65% (from 77±9.1 to 127±18) in
plasma Arginine

Randomized controlled trial
of oral citrulline [88]

40 children undergoing
cardiopulmonary
bypass

5 doses (1.9 g per m2 body
surface area)

- Plasma L-arginine in citrulline group was
significantly higher than placebo group (36
μmol /L vs 26 μmol /L in immediately after
operation; 37 μmol /L vs 20 μmol /L at 12 h after
operation)

A randomized study [98]

Ten healthy volunteers

0.18 g/kg/d

- Citrulline: increase of 448±92% (from 39±4 to
225±44)- Arginine: increase of 92±57% (from
134±33 to 247 ±62)- Increase in urine and RBC
Citrulline- No change in urinary Arginine, nor
plasma urea, urinary urea nitrogen excretion thus
enhanced nitrogen balance

Pharmacokinetic study after
watermelon ingestion [99]

Six healthy adults

3.3 kg wet weight red fruit of
ripe watermelon

- Citrulline: increase from 22 μmol/L to 593
μmol/L (range 386 - 1069) 1 h after ingestion
- Arginine: increase from 65 μmol/L to 199
μmol/L (range 128 - 251) 2 h after ingestion

Pharmacokinetic study after
watermelon ingestion [100]

23 healthy adults

780 g (i.e., 1 g Citrulline),
1560 g (i.e., 2g Citrulline)
watermelon juice for three
weeks

- Low ingestion of watermelon juice:12% increase
in plasma Arginine
- High ingestion of watermelon juice:22%
increase in plasma Arginine, 18% increase in
plasma Ornithine.

Pilot study in patients with
pulmonary
hypercholesterolemia [101]

10 subjects

Oral L-arginine (5 or 7 g)
followed by intravenous Larginine (10 or 30 g) after 8
hours at each of the four
different visits

- Mean Cmax range after oral dose: 42.8 to 46.5
μg/mL
- Mean AUC range after oral dose: 651 to 894
μg.min−1.ml−1.g−1
- Mean AUC range after IV dose: 1762 to 1926
μg.min−1.ml−1.g−1
- Mean non-renal clearance: 564.4 to 586 mL/min
- Mean bioavailability: 0.37 to 0.52

Randomized pilot study in
patients with moderately
severe malaria [103]

78 subjects; 48 in the
observational group
and 30 received Larginine

3, 6, or 12 g L-arginine
infused over 30 minutes

- Follows a two-compartment pharmacokinetic
model
- Clearance from central compartment: 31 Lhr−1
- Clearance from peripheral compartment: 74 Lhr
−1

- Distribution volume (central): 27 L
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- Distribution volume (peripheral): 21 L
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Randomized pilot study in
patients with severe malaria
[104]

8 subjects: two received
saline and 6 received Larginine

12 g L-arginine infused over 8
hours

- Follows a two-compartment pharmacokinetic
model
- Clearance from central compartment: 61.8 Lhr−1
- Clearance from peripheral compartment: 21.4
Lhr−1
- Distribution volume (central): 115 L
- Distribution volume (peripheral): 70.9 L

Phase 1 dose finding study
in patients with sickle cell
disease [105]

8 subjects

Step 1: Bolus L-citrulline 20
mg/kg
Step 2: 7 mg/kg per hour
continuous infusion of Lcitrulline

- Peak plasma concentration of L-citrulline after
bolus dose: 257 μmol/l
- Clearance and distribution volume after bolus
administration were 0.52±0.13 L.h−1.kg-1 and
0.50±0.14 L.kg-1, respectively
- Clearance and distribution volume after
continuous infusion were 0.52±0.17 L.h−1.kg-1
and 0.41±0.02 L.kg-1, respectively

Single-blind crossover study
[97]

8 healthy adults

2, 5, 10 or 15g of Citrulline

- After ingestion of 10 g of Citrulline- Citrulline Tmax = 0.72±0.08 h, Cmax =
2756±70μmol/l
- Arginine Tmax = 1.67±0.05h, Cmax = 280
±1043μmol/l

Double-blind randomized
placebo-controlled crossover
study [96]

20 healthy volunteers

Citrulline: 0.75, 1.5 and 3g
twice daily Arginine:
immediate release (IR) 1g tid,
sustained release (SR) 1.6
twice daily for 1 week

- After load of 3 g Citrulline- Citrulline: Tmax = 0.7±0.1 h, Cmax =
846±45μmol/l- Arginine: Tmax = 1.4±0.1h, Cmax = 149
±42μmol/l

Randomized placebocontrolled trial [88]

40 children undergoing
surgery to correct
congenital heart lesions

Citrulline 1.9 g/m2/dose x 5
The total dose of 9.5g /m2

12h postoperative:
- Citrulline: 37 (18-83) vs 20± (15-29) (placebo)
- Arginine: 36±24 vs. 23±1357 and 85% increases
in mean plasma levels of Arginine and Citrulline,
respectively

‘≥’ = greater than or equal to; ‘<‘ = less than; Arg=arginine; Cmax = maximum plasma concentration; Cit= citrulline; d= day; g= gram; h= hour;
kg= kilogram; L= liter; m2= meter squared; mcg= microgram; MELAS= mitochondrial encephalomyopathy, lactic acidosis and stroke-like
episodes; mg=milligram; mmol= millimole; PAH=Pulmonary Arterial Hypertension; tid= three-times daily; vit = vitamin; μmol= micromole; Tmax
= time after dose to observe maximum plasma concentration
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